Key Insights and Signals – Hospital & Healthcare
|
|
|
Centre Setup
Augusta Health opens outpatient pavilion in Virginia
The healthcare held a ribbon cutting for its new 60,000-square-foot Augusta Health Outpatient Pavilion. The surgery center will have eleven operating and procedure rooms and twenty-four pre- and postoperative recovery rooms. Read More>>
UPMC Lititz opens an orthopedics unit at a hospital
The Hospital has reconfigured space inside its 1500 Highlands Drive hospital to establish a 13-bed, 8,580-square-foot orthopedic unit. The unit also includes a nurse navigator to assist with education and coordinated discharge care. Read More>>
Merger and Acquisition
UPMC announces acquisition of Sports Surgery Clinic for an undisclosed sum
The acquisition is subject to approval by the Competition and Consumer Protection Commission. This deal is a critical development for those involved with the clinic. Read More>>
New Product Development
Moffitt developed a tool to measure Patient Health after Radionuclide Therapy
Moffitt Cancer Center researchers developed a tool to assess how radionuclide therapy, a novel prostate cancer treatment, affects patient-reported outcomes to guide treatment and enhance care. Read More>>
Executive Movements
Wipro GE Healthcare names Chaitanya Sarawate as new MD
Chaitanya Sarawate will also be taking charge as the President & CEO of GE HealthCare, South Asia. Sarawate succeeds Shravan Subramanyam, who is leaving to pursue an opportunity outside the company. Read More>>
CVS Health names Sam Khichi as Exec VP, Chief Policy Officer, and General Counsel
He will manage CVS Health’s legal, compliance, and government affairs teams to make health care more accessible and affordable to improve everyone’s health. Read More>>
Former UPMC nurse named CEO of health IT company
Rose Higgins, a former nurse at UPMC has been named CEO of Dr. Evidence, a medical intelligence platform. After nursing at UPMC, Ms. Higgins served as a leader at HealthMyne, SCIO Health Analytics, and McKesson Corp. Read More>>
Financial and Market Activity
UnitedHealth Group Reports 2022 Results
Optum and UnitedHealthcare saw broad-based growth in 2022. Revenues of USD 324 Bn grew 13% YoY, with double-digit growth at both Optum and UnitedHealthcare. Cash flows from operations stood at USD 26 Bn or 1.3x of net income. Read More>>
|
|
Key Insights and Signals in Medical Devices
|
|
|
Product Launch
NanoString releases Single Cell Spatial Transcriptomics Dataset
The dataset highlights CosMx SMI’s high capability to detect and quantify an average of 1,150 transcripts per cell and maximize biological insights by detecting 676 unique genes. Read More>>
Becton Dickinson launches Glass Prefillable Syringe for Biopharmaceuticals
Effivax’s design enhancements are focused on fill/finish and container reliability to help the company’s biopharmaceutical customers meet the stringent demands of vaccine manufacturing. Read More>>
QIAGEN launches EZ2 Connect MDx Platform for Diagnostic Labs
EZ2 Connect MDx made the IVD platform for automated sample processing widely accessible. The EZ2 Connect MDx enables labs to purify DNA and RNA from 24 samples in parallel in as little as 30 minutes. Read More>>
Centre Setup and Expansion
Stryker launches state-of-the-art neurovascular lab
A neurovascular catheterization lab, a performance lab, and a planned space for physician interaction make up the lab to mimic a hospital experience with the latest technologies and equipment. Read More>>
Thermo Fisher expands its global footprint with a new facility
The company announced the expansion of its global Biologics and Steriles manufacturing with the opening of a new facility in Hangzhou, China. The new facility will support pharmaceutical and biotechnology customers to deliver patient therapies more quickly. Read More>>
Merger and Acquisition
Capsa Healthcare acquires Tryten Technologies
The company acquired Tryten Technologies Inc., a designer, and manufacturer of lightweight, easy-to-maneuver mobile cart solutions. Tryten is the company’s second major brand acquisition in the last year and strategically addresses several healthcare industry trends. Read More>>
GE Healthcare to buy Frances IMACTIS in first acquisition as independent firm
The company has agreed to acquire France-based IMACTIS, which uses computed tomography interventional guidance to aid surgeons in minimally invasive operations. Read More>>
Executive Movement
CytoSorbents appoints Irina B. Kulinets as Senior VP of Global Regulatory Affairs
She will serve as a member of CytoSorbents’ executive management team and will report to Vincent Capponi, President and Chief Operating Officer of CytoSorbents. Read More>>
|
|
Key Insights and Signals in Pharmaceutical
|
|
|
Product Launch
Sanofi seeks to launch a blood disorder drug this year
The company plans to launch a drug for the rare bleeding disorder hemophilia A this year. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi. Read More>>
Merger and Acquisition
Ipsen to bolster Liver Disease Portfolio with Albireo acquisition
The deal, expected to close by the end of Q1 2023, will see Ipsen acquire Albireo for approximately USD 952 Mn. The company will also acquire Albireo’s clinical stage asset A3907, a novel oral systemic apical sodium-dependent bile acid transporter inhibitor. Read More>>
India’s Eris Lifesciences to buy some dermatology brands from Glenmark Pharma
The company would acquire a portfolio of dermatology brands from Glenmark Pharmaceuticals Ltd for USD 41 Mn to deepen its presence in the anti-fungal and anti-psoriasis segments. Read More>>
Partnership
Adalvo and STADA extend their strategic partnership
The extension to the long-standing partnership between Adalvo and STADA involves a variety of delivery forms, including difficult-to-make formulations. The two partners expect the deal to strengthen their position in the generic and value-added medicine sectors. Read More>>
Executive Movement
Amarin Board of Directors appoints Murray W. Stewart
Following the appointment of Dr. Stewart, the Amarin Board will be made up of approximately 70 percent of new independent directors who were named to the Board over the last 12 months. Read More>>
|
|
|
Did you find the newsletter helpful? *|SURVEY: Yes|* *|SURVEY: No|*
|
|
|
Latest Industry Insights from Draup Braindesk
|
|
|
|
AstraZeneca’s path to new treatments focuses on Oncology, Biopharmaceuticals, and Rare Diseases
Oncology
- Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody-drug conjugates, Epigenetics; and Cell therapies.
- Advancing innovative clinical strategies to treat early stages of the disease and relapsed or refractory patients.
- Building expertise and leadership in the most prevalent and highest mortality rate tumor types.
Cardiovascular, Renal, and Metabolism
- CVRM diseases such as heart failure, cardiovascular disease, diabetes, non-alcoholic steatohepatitis (NASH), and chronic kidney disease share common and distinct mechanisms.
- It invested in technologies to develop a level of scientific expertise with a patient-centric approach aimed at better understanding the interplay and potential causal relationship between these diseases.
Respiratory & Immunology
- It focuses on chronic respiratory diseases, including asthma & chronic obstructive pulmonary disease (COPD), and immune-driven diseases such as lupus.
- The approach involves targeting the underlying biology and developing effective new drug modalities & combinations.
Vaccines and Immune Therapies
- It develops highly targeted, long-acting antibodies optimized with half-life extension technology to bring a single vaccine to protect people against coronavirus, flu, and respiratory syncytial virus.
- It continues to advance science in vaccines and immune therapies and works with partners to drive improvements in public health.
Rare Disease
- To transform the people affected by rare diseases by understanding patients’ unique needs, developing innovative medicines, supporting access, and advocating for the rare disease community.
- Innovate by investing in science, platforms, and capabilities, including technologies and research capabilities.
|
|
Startup Spotlight
Company – Prealize Health
Total Funding – USD 37.44 Mn
About: Prealize Health uses machine learning to transform healthcare from reactive to proactive so that more people can live healthier lives. Prealize empowers Employers and Providers to see around the corner by predicting what, why, and when of future risks. Read More>>
|
|
Latest Reports Published in Draup
|
|
|
|
Medtronic Public Limited Company – Account Intelligence Report
Medtronic provides high-technology treatment for patients with cardiac issues, diabetes, Spine related issues by deploying Artificial Intelligence and Machine Learning. Read More>>
|
|
Henry Schein Inc. – Account Intelligence Report
Henry Schein focuses on providing Dentrix Ascend, a cloud-based practice management software to be used as the sole management system for Smile Brands and its affiliate practices. Read More>>
|
|
Here’s what’s new on our Sales Intelligence Platform
Introducing Guest Users
|
|
|
Make collaboration with your colleagues a breeze! Invite your colleagues to Draup as Guest Users and collaborate on projects. Guests are above and beyond your allowed Draup licenses and free of charge (up to 5 guests per paid license). The guest users will have access to My Leads and Signals features in Draup.
|
|
|
|
|
